Sickle Cell Disease Educational Briefing- EDUCATING OUR LAWMAKERS ABOUT SICKLE CELL DISEASE

SHARE YOUR STORY WITH YOUR STATE LEGISLATORS!

Join us as we advocate for those with sickle cell disease at the State of Maryland General Assembly. This is an opportunity to meet with our legislators and educate them about the needs of the sickle cell disease community. We are planning to meet with Maryland Senators and Delegates from various counties. Click here to register!

Share this post

CONTACT US
KEEP IN TOUCH
Sign up for our email list, or follow us on social media, to stay in-the-know about the Maryland Sickle Cell Disease Association
Scroll to Top

Breaking News

FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

On December 8, 2023, “The U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signaling an innovative advancement in the field of gene therapy."